Oxcarbazepin‐induziertes lokalisiertes Ödem am Penis

Oxcarbazepine is a analogue of carbamazepine with anticonvulsant and analgesic activity. We report a case of localized penile edema caused by oxcarbazepine. The association between the drug and the adverse reaction was confirmed by rechallenge test. This is the first reported case of oxcarbazepine‐induced localized penile edema.     

Symptomatic Hyponatremia in Patients on Oxcarbazepine Therapy for the Treatment of Neuropathic Pain

Oxcarbazepine is an FDA approved anticonvulsant medication that has also been used clinically as a treatment for chronic neuropathic pain. Hyponatremia is occasionally seen with the older anticonvulsant carbamazepine, and oxcarbazepine is a derivative of that older drug. Two cases of hyponatremia associated with oxcarbazepine are reported and suggestions for monitoring for and managing this effect are provided.     

The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised,double-blind,placebo-controlled phenotype-stratified study

In neuropathic pain it has been suggested that pain phenotype based on putative pain mechanisms may predict response to treatment. This was a randomised, double-blind, placebo-controlled, and phenotype-stratified study with 2 6-week treatment periods of oxcarbazepine (1800-2400 mg) and placebo. The primary efficacy measure was change in median pain intensity between baseline and the last week of treatment measured on an 11-point numeric rating scale, and the primary objective was to compare the effect of oxcarbazepine in patients with and without the irritable nociceptor phenotype as defined by hypersensitivity and preserved small nerve fibre function determined by detailed quantitative sensory testing. Ninety-seven patients with peripheral neuropathic pain due to polyneuropathy, surgical or traumatic nerve injury, or postherpetic neuralgia were randomised. The intention-to-treat population comprised 83 patients: 31 with the irritable and 52 with the nonirritable nociceptor phenotype. In the total sample, oxcarbazepine relieved pain of 0.7 points (on a numeric rating scale 0-10; 95% confidence interval [CI] 0.4-1.4) more than placebo (P = 0.015) and there was a significant interaction between treatment and phenotype of 0.7 (95% CI 0.01-1.4, P = 0.047). The number needed to treat to obtain one patient with more than 50% pain relief was 6.9 (95% CI 4.2-22) in the total sample, 3.9 (95% CI 2.3-12) in the irritable, and 13 (95% CI 5.3-∞) in the nonirritable nociceptor phenotype. In conclusion, oxcarbazepine is more efficacious for relief of peripheral neuropathic pain in patients with the irritable vs the nonirritable nociceptor phenotype.